In this prospective, nonrandomized, open-label, phase I clinical trial, we sought to assess the safety and preliminary efficacy of combination afatinib and pembrolizumab in patients with advanced NSCLC with EGFR-activating mutations who have experienced disease progression on previous EGFR TKI. This evidence concerns the gene EGFR and non-small cell lung carcinoma.